Pembrolizumab-Induced Eruptive Keratoacanthomas and Lichen Planus in a Lung Cancer Patient

Reports of pembrolizumab-induced lichen planus and eruptive keratoacanthomas are limited in the literature. Here, we describe unique concurrence both a patient who received pembrolizumab for non-small cell lung cancer (NSCLC). Although several therapies have been proposed, show that can be controlled with conservative management topical corticosteroids intralesional corticosteroids, respectively, allowing patients to continue therapy.